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Abstract
Background: Heart failure (HF) involves alterations in metabolism, but little is known about cardiomyopathy-(CM)-specific or
diabetes-independent alterations in gene expression of proteins involved in fatty-acid (FA) uptake and oxidation or in
calcium-(Ca
2+)-handling in the human heart.
Methods: RT-qPCR was used to quantify mRNA expression and immunoblotting to confirm protein expression in left-
ventricular myocardium from patients with HF (n=36) without diabetes mellitus of ischaemic (ICM, n=16) or dilated (DCM,
n=20) cardiomyopathy aetiology, and non-diseased donors (CTL, n=6).
Results: Significant increases in mRNA of genes regulating FA uptake (CD36) and intracellular transport (Heart-FA-Binding
Protein (HFABP)) were observed in HF patients vs CTL. Significance was maintained in DCM and confirmed at protein level,
but not in ICM. mRNA was higher in DCM than ICM for peroxisome-proliferator-activated-receptor-alpha (PPARA), PPAR-
gamma coactivator-1-alpha (PGC1A) and CD36, and confirmed at the protein level for PPARA and CD36. Transcript and
protein expression of Ca
2+-handling genes (Two-Pore-Channel 1 (TPCN1), Two-Pore-Channel 2 (TPCN2), and Inositol 1,4,5-
triphosphate Receptor type-1 (IP3R1)) increased in HF patients relative to CTL. Increases remained significant for TPCN2 in all
groups but for TPCN1 only in DCM. There were correlations between FA metabolism and Ca
2+-handling genes expression. In
ICM there were six correlations, all distinct from those found in CTL. In DCM there were also six (all also different from those
found in CTL): three were common to and three distinct from ICM.
Conclusion: DCM-specific increases were found in expression of several genes that regulate FA metabolism, which might
help in the design of aetiology-specific metabolic therapies in HF. Ca
2+-handling genes TPCN1 and TPCN2 also showed
increased expression in HF, while HF- and CM-specific positive correlations were found among several FA and Ca
2+-handling
genes.
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Introduction
Human heart failure (HF) has been described as a hypera-
drenergic state leading to increased plasma levels of free fatty acids
(FFA), which in turn cause a range of metabolic dysfunctions
including aberrant FA uptake and oxidation in the myocardium
[1]. Therapeutic modulation of FA metabolism [1,2], stimulation
of glucose metabolism [3] and selective targeting of sarcolemmal
transporters of FA or glucose, depending on presence or absence
of diabetes [4] are all currently under consideration. The
putatively adaptive switch from predominantly FA to predomi-
nantly glucose oxidation via the Randle cycle during progression
to myocardial failure has received increasing attention [3,5–7].
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oxidation per se with HF in humans, particularly in relation to
aetiology and treatment, remain poorly understood.
One consistent finding in HF patients is an increase in plasma
levels of Heart Fatty-Acid-Binding Protein (HFABP) which can be
substantial [8–10]. In light of its role in intracellular transport to
the mitochondria where FAs undergo b-oxidation [11], it is of note
that expression levels of HFABP within the myocardium have not
previously been studied in HF patients. Potential alterations in
human HF between cardiac HFABP and its downstream enzymes
of FA oxidation are thus unknown. An important regulator of
HFABP and several subsequent steps in FA utilisation, peroxi-
some-proliferator-activated-receptor-alpha (PPARA) [12,13], has
also been found to have altered expression in human HF [14–16].
HF-related changes in myocardial gene expression have also
been found at various points in the FA uptake and oxidation
pathways in humans and animal models for the following genes:
Cluster-of-Differentiation 36 (CD36, also known as Fatty-Acid
Translocase (FAT) and an important FA transporter across the
plasma and outer mitochondrial membranes) [5,17]; Cardiac
Carnitine Palmitoyl-Transferase-1 (CPT-1, the other principal
outer mitochondrial membrane FA transporter) [15,18,19]; and
Long-Chain Acyl-CoA Dehydrogenase (LCAD, a key enzyme of
b-oxidation) [18,20–22].
PPARA and LCAD are also known to be regulated by PPAR-
gamma coactivator-1-alpha (PGC1A) [23], while altered mito-
chondrial function has been associated with excess levels of plasma
FFA in HF patients [24], and in rodent models with excess FA
levels not only in plasma but also within the cardiomyocyte [25–
27]. However, many discrepancies still exist in the findings of
studies on alterations in the FA uptake-oxidation pathway as a
whole in human HF. This is probably due to HF having been
viewed as a single pathological end-point, rather than as different
aetiology-specific diseases [28,29].
Aberrant lipid metabolism can also disrupt intracellular calcium
(Ca
2+) homeostasis – specifically Ca
2+ cycling and inositol-3-
phosphate receptors (IP3Rs) levels – and cause endoplasmic
reticulum (ER) stress [30–33], one of whose main markers is
known to be the protein CHOP (CCAAT/enhancer-binding-
protein-homology protein) [34,35]. Altered expression of IP3Rs
has previously been identified in cardiac hypertrophy patients
[36]. The two-pore channels TPCN1 and 2 have been recently
identified as a novel class of endo-lysosomal Ca
2+ channels and
likely receptors for NAADP, nicotinic acid adenine dinucleotide
phosphate, the most potent Ca
2+ mobilizing messenger known
[37,38,39].
Our purpose was to look for changes in the expression of
proteins involved in FA uptake and oxidation or in Ca
2+-handling
in the failing human heart, with the aim of defining aetiology-
specific differences between ischaemic and dilated heart failure
patients.
Materials and Methods
Tissue Samples, and Demographic and Clinical
Parameters
Transmural left-ventricular myocardial biopsies were obtained
from explanted human hearts from 16 patients with ICM and 20
patients with DCM, all without diabetes mellitus, in end-stage HF
and undergoing heart transplantation, as previously described
[40,41]. Cardiomyopathy groups were defined according to the
following clinical criteria: ICM: LVEF ,40% with coronary
artery damage on angiogram (the majority having suffered a
previous MI); DCM: LVEF ,40% with intact coronary arteries,
no previous MI, and dilated non-hypertrophic left ventricle on
echocardiography (LVDD .55 mm [40,41]; Table 1). Non-
diseased donor hearts in cardioplegic arrest for a mean time of two
and a half hours, deemed unsuitable for transplant due to blood-
type or size incompatibility, were used to obtain control
myocardial tissue (CTL, n=6; Table 2). The atrial tissue necessary
for the standarization of some of the antibodies used in Western
blot was obtained as pieces of right atrial appendage excised to
allow catheterisation of the right atrium during surgery requiring
cardiopulmonary bypass (tissue which is usually discarded).
All tissues were obtained with signed informed consent of
patients. The project was approved by the local Ethics Committee
(Biomedical Investigation Ethics Committee) and conducted in
accordance with the guidelines of the Declaration of Helsinki.
Real-time PCR
RNA was extracted using a NucleoSpin kit, according to the
manufacturer’s instructions (Macherey-Nagel, Germany). For
relative quantification we performed a reverse-transcription
reaction with 1 mg of RNA using a First Strand kit (Superarray
Bioscience Corp, MD, USA). RNA quality and quantity was
determined using a NanoDrop (Thermo Scientific, Spain)
spectrophotometer. Next, a real-time PCR reaction was per-
formed using the Superarray master mix provided, and 1 mlo f
cDNA in each well, for the following specific human primers:
TPCN1:86 bp, PPH08675A, reference position 2682 RefSeq
NM_017901.4; TPCN2:124 bp, PPH13927 reference position
1550 RefSeq Accession: NM_139075.3; GAPDH: 175 bp,
PPH00150E reference position 1287–1310 GenBank
NM_002046.3. Amplification conditions were: 95uC for
10 min, followed by 40 cycles of 95uC for 15 s and 60uC for
60 s. All Superarray primers were pre-optimised by the manufac-
turer.
A real-time PCR reaction was performed using the Solaris
qPCR Gene Expression Master Mix with LOW ROX premixed,
and 1 mL of total cDNA in each well, for the following specific
human primers: GAPDH: GCCTCAAGATCATCAGCAATG
(forward) and CCTCCACGATACCAAAGTTGTC (reverse),
Probe (GCCAAGGTCATCCATGA), RefSeq Accession
NM_002046; IP3R1: TGGGGCACAACATCTAC (forward)
and CTTTGTTATGCCGAGCCA (reverse), Probe (AT-
Table 1. Patient characteristics according to heart failure
aetiology.
ICM (n=16) DCM (n=20)
Age (yr), mean6SD 53.668.1 46.5611
Gender male, n (%) 16 (100) 17 (85)
NYHA class (1–4), mean6SD 3.6160.3 3.4460.5
BMI (kg/m
2), mean6SD 25.564.0 25.164.6
LVEF (%), mean6SD 23.265.6 19.667.6
LVESD (mm), mean6SD 53.467.4 69.869.4
LVEDD (mm), mean6SD 61.767.3 78.368.8
LV mass (g), mean6SD 258.7654.2 390.86116.4
Duration of disease (m),
mean6SD
37.8646.4 69.5652.6
Duration of disease: from diagnosis to heart transplant; BMI: body mass index;
DCM: dilated cardiomyopathy; ICM: ischaemic cardiomyopathy; LVEF: left
ventricular ejection fraction; EDD: end diastolic diameter; ESD: end systolic
diameter; NYHA: New York Heart Association.
doi:10.1371/journal.pone.0037505.t001
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NM_001099952; PPARA: CCAGTATTTAGGAAGCTGTCC
(forward) and TGAAAGCGTGTCCGTGAT (reverse), Probe
(CTCAGATGGCTCGGTCA), RefSeq Accession NM_032644;
PGC1A: AATTGAAGAGCGCCGTGT (forward) and AACCA-
TAGCTGTCTCCATC (reverse), Probe (AGTAAATCTGCGG-
GATG), RefSeq Accession NM_013261; CPT1B: ACTGCTA-
CAACAGGTGGTT (forward) and
TCTGCATTGAGACCCAACTG (reverse), Probe
(ATTTCCTTCAAGAATGGCC), RefSeq Accession
NM_152247; NM_152245; NM_152246; NM_004377;
CD36: GTTGCCATAATCGACAC (forward) and GCAGT-
GACTTTCCCAATAGG (reverse), Probe (GGTAAAAG-
GAATCTGTCC), RefSeq Accession NM_001001548;
NM_001001547; NM_000072; NM_001127443;
NM_001127444 and LCAD: CTTCCACAG-
GAAAGGCTGTT (forward) and CTGCTAATTTATGTTG-
CACTG (reverse), Probe (GTTGCTCACCTACAGACAGT),
RefSeq Accession NM_001608.
Using primers designed with the Beacon Designer program
(v3.1, Premier Biosoft International, CA, USA) and pre-optimised
conditions, we also performed one-step real-time PCR with the
Brilliant II SYBR Green QRT-PCR Master Mix Kit (Stratagene,
CA, USA) and the same quantity of total RNA in each well (5 ng),
for the following specific human primers: CHOP: CAGAAC-
CAGCAGAGGTCACA (forward) and TCACCATTCGGT-
CAATCAGA (reverse), 210 bp, RefSeq Accession
NM_004083.4; HFABP: CAGCAGATGACAGGAAGG (for-
ward) and CCGATTGGCAGAGTAGTAG (reverse), 218 bp,
RefSeq Accession NM_004102.3; GAPDH: AAGGT-
GAAGGTCGGAGTC (forward) and CCTGGAAGATGGT-
GATGG (reverse), 229 bp, RefSeq Accession NM_002046.3.
Amplification conditions were: reverse-transcription reaction:
50uC for 30 min and 95uC and 10 min; polymerase-chain
reaction: 40 cycles of 95uC for 40 s, 56uC for 60 s, and 72uC
for 40 s. Efficiency curves of 90–110% were obtained.
Results were analyzed using the MxPro v4 software (Stratagene,
CA, USA). PCR experiments for each gene in each donor and
patient were performed in duplicate and the mean value used to
calculate fold-change in expression (2
2DDCt, where DCt=mean
(GOI-Ref) value at threshold cycle; GOI: gene of interest; Ref:
reference gene). ,1% of duplicate experiments were repeated due
to a threshold cycle $35 or difference in threshold cycles of .1.
Experiments were standardised by use of a single pool of extracted
RNA for each donor or patient and in each plate an internal
reference gene (GAPDH) and an external single pool of human
non-ventricular (atrial) RNA. A dissociation curve was obtained at
the end of each experiment to confirm the PCR product.
Immunoblotting
Individual genes showing HF- and CM-related changes in
expression at the RNA level (HFABP, TPCN1, TPCN2, PPARA,
IP3R1, CD36) were then tested at the protein level by
immunoblotting. Tissue was lysed with Triton X-100 (1% buffered
in 50 mmol/L Tris-HCl, 150 mmol/L NaCl, 5 mmol/L EDTA,
1 mmol/L phenylmethylsulphonylfluoride, 10 mg/ml leupeptin,
10 mg/ml aprotinin, 10 mg/ml trypsin inhibitor and 1 mmol/
L NaVO4). Samples were subjected to SDS-PAGE under dena-
turing conditions on 8% (TPCN1, TPCN2), 15% (HFABP), 10%
(PPARA, CD36) and 4–20% (IP3R1) acrylamide gels and
electroblotted onto PVDF membranes (Amersham Pharmacia
Biotech, Germany). Membranes were treated with the following
primary antisera, either at room temperature for 2 h (anti-
PPARA, TPCN1, TPCN2) or at 4uC overnight (HFABP, CD36):
HFABP (1:000; Santa Cruz Biotechnology, CA, USA); anti-CD36
(1:1000; Pierce Biotechnology-Thermo Scientific, IL, USA); anti-
TPCN1 (1:1000) affinity-purified using a standard kit according to
the manufacturer’s protocol (SulfoLink, Thermo Scientific UK)
from rabbit anti-serum raised against specific TPCN1 antigenic
human C-peptides; anti- TPCN2 (1:100; Novus Biologicals, CO,
USA); anti-PPARA (1:1000; Pierce Biotechnology-Thermo Scien-
tific, IL, USA); and anti-IP3R. Membranes were then incubated
with horseradish-peroxidase-conjugated secondary antibody
(1:2000; Santa Cruz Biotechnology, CA, USA) and subjected to
chemiluminescence detection (Millipore Corporate, MA, USA).
Anti-GAPDH (1:1000; Santa Cruz Biotechnology, CA, USA) was
used as a loading control. Densitometric analyses were performed
using a UVP EC3 Imaging System (Ultra-Violet Products Ltd,
UK) and the Image J program (v1.43 q; Rasband 1997–2008).
N-Glycosidase F (PNGase F) Pre-treatment for
Identification of TPCN1 and TPCN2 Protein
Bands in Western Blot
Ours is the first report that includes the identification by western
blot of the protein bands corresponding to TPCN1 and TPCN2 in
human myocardium. In order to standarize a protocol for the
identification of both proteins in human cardiac tissue, and having
into account that in other tissues TPCN1 and TPCN2 are known
to be N-glycosidated [42,43], we first performed several experi-
ments that helped us to identify both proteins in our western blots.
Briefly, and as described previously for HEK 293 cells [42,43],
atrial protein (extract supernatant containing 20 mg total protein)
was incubated with or without 50 000 units/ml N-Glycosidase F
(PNGase F, New England Biolabs, USA) before immunoblotting
as described above. For TPCN2 the manufacturers protocol was
followed, i.e. protein was previously denatured at 100uC for
10 min and then incubated in PNGase F at 37uC for 60 min; for
TPCN1, the denaturing step was omitted and PNGase F
incubation carried out for 120 min.
Comparing PNGase F pre-treated and non-pretreated atrial
protein by immunoblot revealed different protein bands for both
TPCN1 and TPCN2. Thus TPCN1 and TPCN2 expressed
endogenously in human myocardium was shown to be N-
glycosylated. Glycosylation of TPCN1 corresponded with bands
of molecular weights of 130 and 100 kDa which disappeared after
PNGase F pre-treatment, while a more prominent band of 95 kDa
appeared probably due to the protein running at a lower
molecular weight after deglycosylation with PNGase F treatment
(data not shown). Glycosylation of TPCN2 corresponded with two
bands of molecular weights approximately 100 and 85 kDa; while
a band of approximately 80 kDa appeared probably due to the
Table 2. Characteristics of control (CTL) group.
Donor Age Gender Cause of death LVEF
1 16 Female RTA .50
2 58 Male UNK .50
3 56 Male RTA .50
4 56 Male CVA .50
5 54 Female CVA .50
6 51 Male UNK .50
CVA: cerebrovascular accident; LVEF: left ventricular ejection fraction (%, value
assumed); UNK: data not available; RTA: road traffic accident.
doi:10.1371/journal.pone.0037505.t002
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with PNGase F treatment (data not shown).
Statistical Analyses
We used a non-parametric approach because the patient
population did not show a normal distribution for all demographic
or clinical variables investigated (Shapiro-Wilk normality tests).
For mRNA analysis, statistical significance of the differences
between fold-changes in gene expression above baseline (2
2DDCt;
hereafter referred to as gene expression levels) were tested using U
Mann-Whitney, Kruskall-Wallis and post-hoc tests, for CTL, HF,
ICM and DCM groups. For protein-level analysis, U Mann-
Whitney or the Wilcoxon Sign Test was used. Spearman linear
correlation coefficients were then calculated for gene expression
levels, within each of the HF, ICM and DCM groups. SPSS v15.0
(SPSS Inc, IL, USA) and R 2.12.2 (R Development Core Team
(2011) [44] were used. Significance was taken at p,0.05 in all but
post-hoc U Mann-Whitney tests where p,0.016 was considered
significant.
Results
HF- and Aetiology-related Changes in Expression of
Individual Genes of Fatty Acid Metabolism
In HF (n=36) as a whole, mRNA expression for CD36
(p=0.006) and HFABP (p=0.011) was found to be increased
relative to CTL (Table 3 and Fig. 1).
When considering CM-specific groups, mRNA expression of
CD36 (p=0.006) and HFABP (p=0.003) was increased relative to
CTL only in DCM (n=20) but not in ICM (n=16) (Table 3 and
Fig.1).
Analysis by western blot of the protein levels of CD36 confirmed
that expression of this protein was significantly higher (p=0.013,
Mann-Whitney test) in the cardiac tissue of patients with HF of
dilated aetiology (DCM; n=7) than in those of ischaemic aetiology
(ICM; n=7) (Fig. 1).
HFABP protein levels analysis by western blot confirmed that
the expression of this protein was significantly increased only in
HF patients of dilated aetiology (n=6 DCM vs n=3 CTL,
p=0.031) (Fig. 1).
Finally, a direct comparison between ICM (n=16) and DCM
(n=20) using post-hoc tests showed mRNA of the following three
genes to be more highly expressed in DCM than ICM: PPARA
(p=0.015), PGC1A (p=0.010), CD36 (p=0.012) (Table 3 and
Figs.1 and 2).
DCM.ICM was confirmed at the protein level for PPARA
(DCM n=7 vs ICM n=7, p=0.006) (Fig.2).
We did not find significant changes in mRNA expression levels
for the following genes (data not shown): CPT1B, LCAD, CHOP.
HF- and Aetiology-related Changes in Expression of Ca
2+-
Handling Genes
In HF (n=36) as a whole, mRNA expression for TPCN1
(p=0.018), TPCN2 (p=0.001) and IP3R1 (p=0.035) was also
increased relative to CTL (Table 3 and Figs. 3 and 4).
In CM-specific groups, mRNA expression was increased
relative to CTL(n=6): in ICM (n=16), TPCN2 (p=0.008); in
DCM (n=20), TPCN1 (p=0.015) and TPCN2 (p=0.001). These
results were confirmed at the protein level: TPCN1 expression was
increased significantly (p=0.002) in DCM (n=13) relative to CTL
(n=4) and TPCN2 expression was increased significantly in ICM
(n=8; p=0.016) and DCM (n=6; p=0.031) relative to CTL
(n=4) (Table 3 and Fig. 3).
CM-specific Correlations in Gene Expression (Table 4)
Having found specific CM-dependent increases in expression of
four genes (CD36, HFABP, PPARA and PGC1A) involved in FA
metabolism and HF-related increases in three Ca
2+-handling
genes (TPCN1, TPCN2 and IP3R1), we next compared gene
expression levels by calculating Spearman correlation coefficients
within CTL, ICM (n=16) and DCM (n=20) groups; any
correlation with p,0.05 in CTL and p,0.01 in ICM and
DCM was selected for further consideration. Of the 17 distinct
gene pairs found to be correlated, 14 were positive (indicating that
expression of both genes increased or decreased) and 3 were
negative (indicating that expression of one gene increased while
the other decreased) (Table 4).
CTL (n=6)
In terms of correlations between genes involved in FA
metabolism, CD36 was correlated with CPT1B (r=0.89), and
HFABP and PPARA with each other (r=0.89). There were also
correlations between FA metabolism genes and Ca
2+-handling
genes: HFABP and PPARA were each correlated with IP3R1
(r=0.83 in each case), while HFABP was correlated with TPCN1
(r=0.94). PPARA and IP3R1 each had negative correlations with
CHOP (r=20.83 in each case). Thus, in CTL there were 7
correlations among the genes that we studied, all of which had
high ‘r’ values, indicating statistical reliability (Table 4).
ICM (n=16)
There were 6 correlations among the genes that we studied, all
of which were distinct from those found in CTL (Table 4). CD36
was correlated with PPARA (r=0.74) and PGC1A (r=0.68),
while PPARA was also correlated with PGC1A (r=0.63). Both
CD36 and PPARA were correlated with TPCN1 (r=0.67 and
r=0.78, respectively). TPCN2 was negatively correlated with
CHOP (r=20.66).
DCM (n=20)
CD36 was correlated with PPARA, LCAD and PGC1A
(r=0.93, r=0.62, and r=0.60 respectively), while PPARA was
also correlated with LCAD and PGC1A (r=0.71 in each case).
Finally, in this group CHOP showed its only positive correlation
with the genes that we studied, with TPCN1 (r=0.64). Thus, while
we also found 6 correlations in this group which were distinct from
Table 3. Increases in myocardial gene expression in heart
failure groups, according to cardiomyopathic aetiology.
Gene Comparisons vs. CTL ICM vs.DCM
HF ICM DCM
CD36 p=0.006 ns p=0.006 p=0.012
HFABP p=0.011 ns p=0.003 ns
PPARA ns ns ns p=0.015
PGC1A ns ns ns p=0.010
TPCN1 p=0.018 ns p=0.015 ns
TPCN2 p=0.001 p=0.008 p=0.001 ns
IP3R1 p=0.035 ns ns ns
mRNA expression in heart failure (HF, n=36) and aetiological groups of HF,
compared with Control (CTL, n=6) and directly between two groups: ICM
(n=16): ischaemic cardiomyopathy; DCM (n=20): dilated cardiomyopathy. ns:
not significant.
doi:10.1371/journal.pone.0037505.t003
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(Table 4).
Discussion
This study investigated HF-related alterations in ventricular
myocardial expression of genes along the PPARA- PGC1A-
HFABP-b-oxidation pathway. In human HF of DCM but not
ICM aetiology we found significant increases in expression over
CTL levels of genes regulating FA uptake (CD36/FAT) and
intracellular transport (HFABP). The high levels of significance
found at the RNA level together with confirmation at the protein
level show that all the groups were statistically reliable. Further-
more, comparison of the two aetiological groups with each other
showed that CD36, PPARA and PGC1A were all significantly
more highly expressed in DCM than ICM. Interestingly,
expression of all three genes was correlated in both DCM and
ICM, but not in CTL.
As PPARA is an important regulator of HFABP and CPT1B,
and PGC1A co-activates PPARA and regulates b-oxidation
[6,12,13,23], our results suggest that there is a general up-
regulation of the PPARA- PGC1A-HFABP-b-oxidation pathway
in HF of DCM but not ICM aetiology. Our findings with PPARA
are consistent with those of Schupp and colleagues [15] who found
that LV myocardial expression of PPARA was increased at both
mRNA and protein levels in 16 DCM patients compared with 15
CTL. In endomyocardial septal tissue from patients with HF of
hypertrophic non-DCM aetiology no differences were found in
PPARA mRNA expression; intriguingly, expression of the native
protein was decreased but truncated protein increased in the same
non-DCM group [16]. Although our tissue may have some
different characteristics from those studied by Goikoetxea and
colleagues [16], our results are in general agreement: compared
with CTL, our non-DCM tissue did not show increased expression
of PPARA either for mRNA or native protein; we did not study
expression of the truncated form of the PPARA protein. The only
Figure 1. HF- and aetiology-related changes in expression levels of individual genes/proteins of fatty acid metabolism. A. Increased
human myocardial expression of Cluster-of-Differentiation 36 (CD36) in heart failure as a whole (HF) and aetiological groups in absence of diabetes
mellitus (ischaemic or dilated cardiomyopathy (ICM, DCM) and compared with non-diseased donors (CTL). i. box-plot of mRNA expression, showing a
significant increase over CTL (n=6) for HF (n=36, Mann-Whitney p=0.006) and DCM (n=20, post-hoc p=0.006), but not ICM (n=16); mRNA was also
more highly expressed in DCM than ICM (post-hoc p=0.012); ii. densitometry analysis of protein expression from immunoblots, showing a significant
increase over ICM (n=7) for DCM (n=7, p=0.013); iii. representative immunoblot for ii. B. Increased human myocardial expression of Heart-Fatty-
Acid-Binding Protein (HFABP) with respect to heart failure as a whole and aetiological groups in absence of diabetes mellitus. i. box-plot of mRNA
expression, showing a significant increase over non-diseased donors (CTL, n=6) for HF (n=36, p=0.011) and DCM (n=20, p=0.003), but not ICM
(n=16); ii. densitometry analysis of protein expression from immunoblots, showing a significant increase over CTL (n=3) for DCM (n=7, p=0.031);
iii. representative immunoblot for ii. (a.u.: arbitrary units).
doi:10.1371/journal.pone.0037505.g001
Fatty Acid and Calcium Metabolism in Failing Heart
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e37505other report of altered PPARA expression in human HF has also
shown mRNA to be unaffected, although native protein expression
was decreased; however that study involved only five patients with
apparently undefined HF aetiology [14].
Similar to our findings, Karamanlidis and colleagues have also
recently reported that expression of neither PPARA nor PGC1A is
altered at the mRNA level in failing left ventricular myocardium
when HF taken as a whole [45]. Notably, that study did find a
substantial increase in protein expression for PGC1A in the HF
group as a whole (n=23) over non-HF (n=19), although it did not
find differences in either mRNA or protein levels between the two
CM groups that made up HF (ICM (n=9) and non-ICM (n=14)).
Other studies using human myocardium samples from different
populations of end-stage heart failure patients have found
increased [22,46] or decreased mRNA expression in HF for
PGC1A [46,47]. Due to the variability that exist in the patient
population between the different studies, differences in the
therapies followed by the patients (some authors have proposed
that angiotensin-converting enzyme inhibitors have a direct effect
on cardiac remodelling and energy metabolism [48]) or in the
clinical characteristics of the individuals (specially metabolic
disorders such as diabetes; to note, we have selected for this study
only non diabetic patients) could account in part for those
controversial results.
Using experimental animal models of heart failure, other
authors have reported unchanged or increased myocardial gene
and/or protein expression levels of PGC1A and PPARA in rats
[49,50]; however, these results, obtained in rodents in which heart
failure was induced after three weeks of aortic banding or by
feeding for 17 weeks with high salt diet, are hardly comparable
with those obtained in human failing myocardium.
Due to the limited amount of human tissue available to us, we
did not study protein expression for genes in which mRNA levels
were unchanged (i.e. in HF as a whole). However, having found
that PPARA mRNA levels were significantly greater in DCM than
ICM, we confirmed that at the protein level. Thus, compared with
Karamanlidis and colleagues [45], we have found an additional
CM-related alteration in PPARA expression. Moreover, our CTL
and DCM groups were more strictly defined than the respective
non-HF and non-ICM groups used in that study [45]. It should
also be noted that although our CTL group comprised 6
individuals, our data-set from them was statistically reliable, as
shown by several highly significant alterations in expression
between CTL and various HF groups, as well as the tight
Spearman correlations obtained within the CTL group. The same
series of patients and donors has, moreover, been used in recently
published studies [51,52].
Our study did not show HF-related alterations in mRNA
expression of either of the mitochondrial transport gene CPT1B or
the b-oxidation gene LCAD, which are downstream of PPARA
and PGC1A. This is in agreement with a previous study [45].
Other studies collectively show several discrepancies, with HF-
related increases [18] or decreases in mRNA expression of CPT1B
[46], and either unchanged mRNA [18] or decreased LCAD
protein [20,22,46]. It should be noted that these studies have
involved smaller numbers of patients of defined [22], non-defined
[20], or mixed [18,46] HF aetiology.
Two previous studies have analyzed the expression of CD36 in
human failing myocardium: Pohl et al. [53] found no differences
in CD36 expression in the plasma membranes of cardiomyocytes
in patients with dilated cardiomyopathy, whereas Uray et al. [54]
showed a transcriptional upregulation of CD36 linked to reverse
remodelling in end-stage heart failure patients. Ours is, however,
the first report of CD36 expression being increased in human HF
in the absence of diabetes mellitus, or analysed in terms of ICM or
DCM, but our results, taken together with the data for PPARA,
PGC1A and HFABP and previous reports of increased FA levels
perturbing mitochondrial function [24,26–28] could make sense in
one or more ways. In mouse myocardium, over-expression of
PPARA has been shown to lead to over-expression of CD36 [55],
and CD36 contains a PPARA-response element [56]. However,
this effect might be indirect in cardiac [57,58] and skeletal muscle
[59]. Thus, CD36 could have been up-regulated at the sarcolem-
ma and therefore account in terms of FA transport for the
increases we observed in those intracellular components of the FA
metabolism pathway. Alternatively or as well, CD36 might have
been up-regulated at the mitochondrial membrane. Due to the
limited amount of tissue available, we could not carry out cellular
Figure 2. Different human myocardial expression of peroxisome-proliferator-activated-receptor-alpha (PPARA) between the two
heart failure aetiological groups in absence of diabetes mellitus. i. box-plot of mRNA expression, showing a significant increase in DCM
(n=20) compared with ICM (n=16, p=0.015); ii. densitometry analysis of protein expression from immunoblots, showing a significant increase in
DCM (n=7) compared with ICM (n=7, p=0.006); iii. representative immunoblot for ii. (a.u.: arbitrary units).
doi:10.1371/journal.pone.0037505.g002
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a hypertrophic group of patients Heather and colleagues [60] have
recently found a positive correlation between HFABP and CD36
at the protein level.
To summarise, this is the first time that CM-related diabetes
mellitus independent differences have been reported in expression
of genes involved in FA uptake, intracellular transport and
oxidation in the same patients with failing human myocardium. It
is notable that we also found potential alterations in the mutual
regulation of some of these genes. Thus, in CTL CD36 was
positively correlated with CPT1B, the principal mitochondrial
membrane FA transporter, whereas in DCM it was correlated
instead with the intra-mitochondrial b-oxidation enzyme LCAD.
In ICM, by contrast, CD36 was correlated with neither of those
mitochondrial factors but instead with the nuclear factors PPARA
and PGC1A. HFABP was correlated only with PPARA and only
in CTL. Taken together, these data suggest that regulation of
CD36, HFABP and PPARA may differ not only in HF- but in
CM-specific ways. On the other hand, there could also be
alterations in gene regulation that are HF-related but not
necessarily CM-specific, as seen by the positive correlations we
Figure 3. Increased human myocardial expression of Two-Pore Calcium channels TPCN1 and TPCN2 in heart failure as a whole (HF)
and aetiological groups (ischaemic or dilated cardiomyopathy, ICM, DCM) and compared with non-diseased donors (CTL). A. Box-
plot of TPCN1 and TPCN2 mRNA expression, showing for TPCN1 a significant increase over CTL (n=6) for HF (n=36, p=0.018) and DCM (n=20,
p=0.015); and for TPCN2 a significant increase over CTL (n=6) for HF (n=36, p=0.001), ICM (n=16, p=0.008) and DCM (n=20, p=0.001). B.
Densitometry analysis and representative immunoblot of TPCN1 protein expression showing a significant increase over CTL (n=4) for DCM (n=13,
p=0.002). C. Densitometry analysis and representative immunoblot of TPCN2 protein expression showing a significant increase over CTL (n=4) for
both ICM (n=8, p=0.016) and DCM (n=6, p=0.031). (a.u.: arbitrary units).
doi:10.1371/journal.pone.0037505.g003
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ICM but not CTL.
We also found HF-related increases in expression of three genes
involved in intracellular Ca
2+ handling. Our increases in
expression of IP3R1 in HF as a whole are in agreement with
those that have previously established increased IP3R expression to
be a general mechanism underlying changes in Ca
2+-signalling in
heart disease [33]. Interestingly, we also found highly significant
HF-related increases in gene expression of the novel endo-
lysosomal Ca
2+ channels TPCN1 and TPCN2, recently identified
as endo-lysosomal Ca
2+ channels and components of the receptor
for NAADP, the most potent intracellular Ca
2+ mobiliser known
[38,39]. The up-regulation of both TPCN1 and TPCN2 that we
found in HF could be related to the results of other studies showing
increased expression of ryanodine receptors (RyR) in failing
human myocardium [61,62]. TPCN2, moreover, had similar
levels of significance in all HF groups that we analysed, regardless
of CM, therefore suggesting for the first time that TPCN2 up-
regulation could also be involved in a general mechanism
underlying heart failure, at least with ICM and DCM aetiology.
Figure 4. Increased human myocardial expression of Inositol-3-Phosphate Receptor sub-type 1 (IP3R1) in heart failure as a whole
(HF, n=36). i. Box-plot of mRNA expression, showing a significant increase over CTL (n=6, p=0.035); ii. representative immunoblot for protein
expression of IP3R1. (a.u.: arbitrary units).
doi:10.1371/journal.pone.0037505.g004
Table 4. Spearman correlations in myocardial gene expression, in control and cardiomyopathy groups.
Gene CD36 HFABP CPT1B LCAD PGC1A IP3R1 TPCN1 CHOP
PPARA 0.74**(2) 0.89*(1) 0.71**(3) 0.63**(2) 0.83*(1) 0.78**(2) 20.83*(1)
0.93**(3) 0.71**(3)
CD36 0.89*(1) 0.62**(3) 0.68**(2) 0.67**(2)
0.60**(3)
HFABP 0.83*(1) 0.94**(1)
IP3R1 0.71**(3) 20.83*(1)
TPCN1 0.64**(3)
TPCN2 20.66**(2)
Numerical values indicate strength (Spearman ‘r’) and asterisks level of significance (*p,0.05, **p,0.01) of correlations in expression between genes in three groups:
control (1, n=6); ischaemic cardiomyopathy (2, n=16); dilated cardiomyopathy (3, n=20). ‘r’ values were positive except for three correlations with CHOP.
doi:10.1371/journal.pone.0037505.t004
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in HF as a whole also tended towards a CM-difference. Thus,
TPCN1’s increase in expression over CTL levels was statistically
significant in DCM for both transcript and protein, whereas in
ICM the transcript and the protein levels tended towards an
increase that did not reach statistical significance. However,
pertinent to a possible role in ICM, TPCN1 expression was
correlated with that of CD36 and also of PPARA in ICM only.
Indeed, those were the strongest (highest r values) and most
significant HF-related correlations found between any Ca
2+-
handlers and any FA pathway gene in all HF groups that we
studied (not all correlation data are shown). In contrast, in CTL,
HFABP was strongly correlated with both IP3R1 and TPCN1, and
PPARA with IP3R1.
The current data provide the first evidence that the endo-
lysosomal system might be involved in cardiomyopathic alterations
in Ca
2+ signalling. It is already known that in failing myocardium
IP3R from the ER becomes more highly expressed at the
junctional sarcoplasmic reticulum (SR) where RyR is located,
causing RyR to become sensitized and increasing diastolic Ca
2+
levels and other Ca
2+ transients characteristic of human heart
failure [36]. In other systems, the central role of lysosomes is now
becoming recognised. TPCNs having been shown to trigger global
Ca
2+ release by recruiting Ca
2+-induced Ca
2+-release (CICR) at
lysosomal-ER junctions and to regulate plasma membrane
excitability by the targeting of Ca
2+-release from sub-plasma
membrane stores, thereby regulating plasma membrane Ca
2+-
activated channels (recently reviewed by Galione [63]). Based on
those studies and our current data, therefore, it may be
hypothesised that in failing myocardium TPCN1 and/or TPCN2
are involved in altered distribution of Ca
2+ to the SR and thereby
to changes in membrane excitability that are known to occur in
failing human heart [64].
Limitations of the Study
1) Due to the limited amount of human tissue available (and the
relatively large number of genes we investigated) we could not
carry out protein level expression analyses for all genes,
comparisons in gene expression with glucose transporters, or
functional studies. 2) The cardioplegic solution used in the
transplant protocols to preserve the condition/function of the
hearts can decrease cardiac energy metabolism.
Conclusions
In conclusion, using relatively large numbers of failing
myocardial samples of ICM or DCM aetiology, we have found
DCM-specific increases in expression of several important genes in
the FA uptake and b-oxidation pathway. We have also found HF-
related increases in expression of the novel endo-lysosomal Ca
2+
handlers, TPCN1 and TPCN2; while TPCN2 was increased in all
HF groups that we analysed, TPCN1 showed potential CM-
specificity which merits further investigation. Finally, several of the
genes investigated were found to be correlated, with patterns that
differed between CTL and HF groups, suggesting HF- and CM-
related alterations in the regulation of genes involved in FA and
Ca
2+myocardial metabolism. We therefore propose that pharma-
cological modulation of FA metabolism in HF as advocated by
Opie [1] and Lionetti [2], among others, should be CM-specific in
design, in particular for idiopathic DCM in which FA uptake and
ß-oxidation are increased with respect to ICM.
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